Eli Lilly plots NDA as second JAK study backs baricitinib for alopecia areata; Alnylam heads to FDA after full vutrisiran data pan out
Eli Lilly has posted positive data from its second Phase III study testing its JAK inhibitor baricitinib in spurring hair regrowth …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
